This company is no longer active
Tricida Valuation
Is 1T7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1T7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 1T7's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 1T7's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1T7?
Other financial metrics that can be useful for relative valuation.
| What is 1T7's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$406.20k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -1x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 1T7's PB Ratio compare to its peers?
| Company | PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
27N0 Cannovum Cannabis | n/a | n/a | €864.8k |
SBX SynBiotic | 0.8x | 134.2% | €19.1m |
B8F Biofrontera | 2.1x | n/a | €29.2m |
APPH Apontis Pharma | 1x | 68.2% | €37.8m |
1T7 Tricida | n/a | 57.3% | €406.2k |
Price-To-Book vs Peers: 1T7 is good value based on its Price-To-Book Ratio (-0x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does 1T7's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Book vs Industry: 1T7 is good value based on its Price-To-Book Ratio (-0x) compared to the European Pharmaceuticals industry average (2.1x)
Price to Book Ratio vs Fair Ratio
What is 1T7's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -0.004x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 1T7's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.